Bayer Management Changes May Suggest Deepening Xarelto Concerns

Delayed appointments of new CEO and CFO may strengthen German pharma's M&A capabilities.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet